Hologic, Inc. $HOLX Stake Boosted by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. boosted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 275.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 666,053 shares of the medical equipment provider’s stock after purchasing an additional 488,525 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.30% of Hologic worth $49,614,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in HOLX. NewEdge Wealth LLC lifted its position in shares of Hologic by 3.8% in the 3rd quarter. NewEdge Wealth LLC now owns 3,779 shares of the medical equipment provider’s stock worth $281,000 after buying an additional 138 shares during the last quarter. Savant Capital LLC lifted its holdings in Hologic by 0.9% in the third quarter. Savant Capital LLC now owns 19,776 shares of the medical equipment provider’s stock worth $1,335,000 after acquiring an additional 170 shares during the last quarter. UMB Bank n.a. lifted its holdings in Hologic by 38.7% in the third quarter. UMB Bank n.a. now owns 620 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 173 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in Hologic by 6.9% in the third quarter. Farther Finance Advisors LLC now owns 2,712 shares of the medical equipment provider’s stock valued at $183,000 after acquiring an additional 174 shares during the period. Finally, OneDigital Investment Advisors LLC boosted its stake in Hologic by 3.2% in the third quarter. OneDigital Investment Advisors LLC now owns 6,105 shares of the medical equipment provider’s stock valued at $412,000 after acquiring an additional 191 shares during the period. Institutional investors own 94.73% of the company’s stock.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $75.55 on Wednesday. The firm’s 50 day moving average is $75.19 and its two-hundred day moving average is $73.15. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $75.75. The firm has a market capitalization of $16.87 billion, a P/E ratio of 31.48, a PEG ratio of 2.24 and a beta of 0.73. The company has a current ratio of 4.04, a quick ratio of 3.32 and a debt-to-equity ratio of 0.48.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). The business had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.07 billion. Hologic had a net margin of 13.18% and a return on equity of 19.58%. The business’s quarterly revenue was up 2.5% on a year-over-year basis. During the same period last year, the firm posted $0.87 EPS. Analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analysts Set New Price Targets

HOLX has been the topic of a number of research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Hologic in a research report on Wednesday, January 28th. Argus lowered Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Finally, Evercore downgraded Hologic from an “outperform” rating to an “in-line” rating and lowered their price objective for the stock from $79.00 to $78.00 in a research note on Monday, January 5th. Two equities research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $78.42.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.